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A cross-sectional community-based study shows that strictly lobar cerebral microbleeds are 
associated with cognitive impairment, and might be a surrogate marker for early small-
vessel injury. The anatomical distribution of cerebral microbleeds suggests that cerebral 
amyloid angiopathy (with or without Alzheimer disease) might play a key role in early 
cognitive impairment. 
  
Refers to Chung CP. et al. Strictly lobar cerebral microbleeds are associated with cognitive impairment.  
Stroke. http://stroke.ahajournals.org/content/early/2016/09/13/STROKEAHA.116.014166 
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Cerebral microbleeds (CMBs) have been associated with cognitive impairment, but the nature of 
the relationship and the mechanisms involved are unclear. In this context, the locations of CMBs 
are of great interest, because they are likely to indicate underlying small vessel pathology that 
underlies the cognitive dysfunction. A community-based Taiwanese population study by Chung 
et al., recently published in Stroke1, adds important new data. The study shows that strictly lobar 
CMBs are associated with cognitive impairment, providing further insight into the likely 
pathogenic mechanisms, and, specifically, suggesting that cerebral amyloid angiopathy (CAA) 
and Alzheimer disease (AD) might be important contributory factors. 
In the late 1990s, advances in MRI techniques allowed in vivo detection of very small 
foci of chronic blood products in the brains of patients with cerebral small vessel disease (SVD). 
These lesions, now commonly referred to as cerebral microbleeds (CMBs)2, cause strong 
paramagnetic distortion of the local magnetic field (so-called blooming), making them 
conspicuous on T2*-weighted gradient-recalled echo sequences or susceptibility-weighted MRI 
sequences2; they appear as small (<10 mm diameter), rounded, homogeneous, hypointense 
lesions. Usually, CMBs correspond pathologically to near-microscopic (<1–2 mm diameter) 
clusters of haemosiderin-laden macrophages close to small vessels with impaired integrity of the 
blood– brain barrier. CMBs were initially considered to be clinically silent, but multiple hospital-
based and population-based MRI studies have demonstrated that they are consistently associated 
with not only cerebrovascular disease, but also neurocognitive disorders, including AD and 
subcortical vascular dementia. 
Early evidence that CMBs are associated with cognitive impairment came from a small 
hospital-based cross-sectional case–control study, which showed that executive dysfunction in 
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patients with stroke was more common among patients with CMBs than in patients without3. This 
observation was supported by a subsequent study of a healthy population, which demonstrated 
that global cognitive dysfunction measured with the Mini-Mental State Examination (MMSE; 
particularly the “attention and calculation” score) was independently associated with both the 
presence and number of CMBs4.  
CMBs are of major interest because their topographical distribution is related to the 
likely underlying pathology (FIG. 1). Indirect evidence suggests that arteriolosclerosis (also 
known as hypertensive arteriopathy or deep perforator arteriopathy) affects deep basal ganglia, 
the brainstem and white matter perforator vessels, causing CMBs in deep (basal ganglia) or 
infratentorial regions and lobar regions5, whereas CMBs, with a strictly lobar distribution are 
highly specific for pathology-proven CAA6 in people with European ancestry and who have 
intracerebral haemorrhage, though this pattern might not be so specific in Asian people or healthy 
non-hospital (community) populations. Interest has, therefore, focused on whether different CMB 
patterns (reflecting different arteriopathies) are associated with different impacts on cognitive 
function, but studies have produced inconsistent results. 
In the ongoing I-Lan Longitudinal Aging Study (ILAS) of randomly selected 
community-dwelling individuals aged >50 years, Chung et al. 1 investigated the associations 
between the presence and locations of CMBs and function in a variety of cognitive domains. The 
study included 959 healthy individuals with a mean age of 62.5 years (SD 8.6 years), 44.3% of 
whom were male. CMBs were assessed with 3T 3D susceptibility imaging, and were found in 
14.2% of participants. The group with CMBs were subdivided into two groups: those with deep 
or infratentorial CMBs (with or without lobar CMBs) and those with strictly lobar CMBs. Global 
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cognitive function was assessed with the MMSE; specific tests assessed verbal memory, language 
ability, visuospatial executive function and verbal executive function.  
Multivariate linear logistic regression analyses, adjusted for potential confounders, 
were used to test whether whole-brain, deep or infratentorial, or strictly lobar CMBs (each tested 
separately) were associated with cognition. The results showed that the presence of CMBs was 
associated with global cognitive dysfunction, but that strictly lobar CMBs correlated with deficits 
in global cognitive and visuospatial executive functions, whereas deep or infratentorial CMBs 
were not associated with cognitive dysfunction. Previously, an association of cognitive 
impairment with strictly lobar CMBs had mainly been observed in Western cohorts, whereas in 
Asian populations, the association was stronger with deep or infratentorial CMBs; we suggested 
that these findings might have been influenced by the dominant patterns of CMBs that occur in 
each population — mainly strictly lobar CMBs in Western populations, and mainly deep or 
infratentorial CMBs in Asian populations5. The ILAS study suggests that strictly lobar CMBs 
could be associated with cognitive impairments, even in Asian populations1.  
This study thus provides additional insight into the unclear relationship between CMBs 
and cognitive dysfunction. The CMBs themselves might have direct causal effects by disrupting 
structural or functional white matter connectivity, or by reducing cortical–subcortical connections 
or cortical neuronal density and function. Alternatively, CMBs might be an indirect marker for 
impaired structure or function of small vessels due to either CAA, deep perforator arteriopathy 
(arteriolosclerosis), or a combination of both7. Another key implication of the study by Chung et 
al.1 is that strictly lobar CMBs might be an early (or even pre-clinical) marker of microvascular 
and neurodegenerative processes that underlie the pathogenesis of cognitive impairment.  
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The exact mechanisms that underlie the relationship between strictly lobar CMBs and 
cognitive decline remain to be determined. Strictly lobar CMBs could be linked to early cognitive 
impairment, including preclinical AD, through vascular amyloid-β (Aβ) damaging the 
neurovascular unit causing, hypoperfusion from stenosis, impaired vascular autoregulation or 
reactivity, or even small areas of microinfarction8. Indeed, strictly lobar CMBs might be the “tip 
of iceberg” of CAA-related dysfunction in widespread cortical small vessels. On the other hand, 
arteriolosclerotic or CAA-related small vessel dysfunction, both of which can cause lobar CMBs, 
could diminish the pulsatility of arterioles, blocking bulk flow and impairing perivascular 
drainage and amyloid clearance from the brain.  
Regardless of the underlying mechanisms, prospective evidence from another study 
supports the hypothesis that lobar CMBs increase the risk of cognitive decline; this study involved 
3,257 non-demented healthy participants from Rotterdam, Netherlands, who were monitored for 
nearly 5 years9. Lobar CMBs were associated with a decline in executive function, information 
processing and memory function. 
Identification of early processes that underlie cognitive impairment is critical to enable 
the design of effective treatments. Indeed, effective selection of patients in the early phase of 
disease by using amyloid ligand PET was probably what led to positive results in the first 
successful trial of immunotherapy in AD, in which the antibody aducanumab reduced Aβ plaques 
and slowed cognitive decline10. As this study demonstrates, molecular PET imaging with ligands 
such as florbetapir or 11C-Pittsburgh compound B is a promising noninvasive examination for the 
detection of early CAA or AD, but is costly and not widely available. The ILAS study suggests 
that strictly lobar CMBs are relevant to early cognitive impairment, and might, therefore, offer 
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another way to detect vascular-related amyloid deposition at an early stage.  
Whether strictly lobar CMBs do indeed reflect the development of early CAA or AD 
in healthy cohorts could be investigated further by looking at correlations of these CMBs with 
cerebral atrophy measurements or amyloid deposition detected with PET. Studies that compare 
distributions of CMBs in people from different geographical populations and ethnicities will also 
be of major interest, as the spectrum of SVD that is relevant to cognition might vary worldwide. 
For the moment, however, this study emphasizes that CMB-related SVD, especially related to 
strictly lobar CMBs, plays a critical role in the earliest stages of cognitive impairment, with 
potential relevance to patient selection and the design of effective treatments for cognitive 
impairment associated with increased SVD and cerebral amyloid (including CAA or AD).  
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Figure legends 
 
Figure 1 | Anatomical location of cerebral microbleeds (CMBs) in cerebral amyloid 
angiopathy (CAA) and deep perforator arteriopathy (arteriolosclerosis). Typical locations of 
CMBs are shown as dark red spots in the brain parenchyma. a | CAA. Amyloid-β peptide 
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accumulates in the walls of small and medium arteries and superficial perforating arterioles (solid 
line square) strictly located in the leptomeninges and the cerebral cortex. b | Deep perforator 
arteriopathy (arteriolosclerosis). The deep basal ganglia, brainstem and white matter (superficial) 
perforating arteries are affected (dashed square), causing CMBs in deep (basal ganglia) or 
infratentorial regions, as well as lobar regions.  
 
 
 
 
 
